A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus Aureus

Antimicrobial Agents and Chemotherapy 2016
A. Gupta, C. Monteferrante, Dace Rasiņa, G. Leitis, C. P. Randall, J. H. Tomlinson, Aigars Jirgensons, W. H. F. Goessens, J. P. Hays, A. J. O`neill

GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P329) within the editing domain of LeuRS.

DOI
10.1128/AAC.02940-15
Hipersaite
http://aac.asm.org/content/60/5/3219

Gupta, A., Monteferrante, C., Rasiņa, D., Leitis, G., Randall, C., Tomlinson, J., Jirgensons, A., Goessens, W., hays, J., O`Neill, A. A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus Aureus. Antimicrobial Agents and Chemotherapy, 2016, Vol.60, 3219.-3221.lpp. ISSN 0066-4804. Pieejams: doi:10.1128/AAC.02940-15

Publikācijas valoda
English (en)